Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00845013

Enrollment

365

Registered

2009-02-16

Start date

2007-11-30

Completion date

2021-01-31

Last updated

2021-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Function, HIV Infection, HIV Infections, Pulmonary Hypertension

Keywords

HIV infection, pulmonary hypertension, endothelial function, antiretroviral medication, Treatment Experienced

Brief summary

The purpose of this study is to describe the epidemiology of pulmonary hypertension in individuals with HIV infection and to investigate its pathogenesis. We propose to conduct a prospective observational cohort study to determine the association between highly active antiretroviral therapy (HAART) and viral suppression in HIV-infected patients who have been identified to have pre-clinical pulmonary hypertension (Aim 1). In addition, we will investigate the mechanistic role of the HIV-1 Nef protein and HHV-8 infection in the development and progression of pulmonary hypertension in individuals with HIV (Aim 2). We will also investigate endothelial function in HIV-infected patients with pulmonary hypertension (Aim 3).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Infection with HIV greater than 6 months in duration 2. Right heart catheterization showing PASP \> 30mm Hg 3. Ability to provide reliable history of HIV medications or has received the majority of medical care from San Francisco General Hospital with available records of medical treatment. 4. Ability to participate in follow-up for the duration of the study.

Exclusion criteria

1. Known significant cardiovascular disease, including clinically significant valvular heart disease, congenital heart disease, current or prior symptomatic coronary disease, or known cardiomyopathy. 2. Any known pulmonary disease that could potentially cause pulmonary hypertension. 3. A pO2 by pulse oximetry below 90% on room air. 4. Obstructive sleep apnea. 5. Known collagen vascular disease. 6. History of anorexigen use * 7\. Age less than 18 years old. * 8\. Other co-morbidities for which the investigators, in conjunction with the primary care provider, believe render the participant with an expected survival of 6 months or less.

Design outcomes

Primary

Measure	Time frame
pulmonary artery pressure	3 years

Countries

United States

Outcome results